EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
145.42
-1.90 (-1.29%)
At close: 4:04PM EDT
Stock chart is not supported by your current browser
Previous Close147.32
Open147.91
Bid136.76 x 800
Ask0.00 x 800
Day's Range145.18 - 149.07
52 Week Range100.20 - 175.00
Volume4,373,502
Avg. Volume1,560,398
Market Cap30.449B
Beta (3Y Monthly)0.53
PE Ratio (TTM)47.76
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Edwards Lifesciences To Host Earnings Conference Call On October 23, 2018
    PR Newswire12 days ago

    Edwards Lifesciences To Host Earnings Conference Call On October 23, 2018

    IRVINE, Calif. , Oct. 9, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve
    PR Newswire13 days ago

    Edwards Announces Start Of U.S. Study Of Self-Expanding Transcatheter Heart Valve

    IRVINE, Calif., Oct. 8, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has commenced the U.S. pivotal trial that will study its self-expanding CENTERA transcatheter valve for severe, symptomatic aortic stenosis (AS) patients at intermediate risk of open-heart surgery. "We are pleased to launch this rigorous study, which we believe will build a robust body of evidence to support the use of this feature-rich, self-expanding valve system in the treatment of patients with aortic stenosis," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. Separately, Edwards confirmed it has updated its regulatory filings and is now resuming the commercial introduction of the CENTERA valve in Europe after completing the previously announced minor modification to CENTERA's delivery system.

  • Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule
    PR Newswire25 days ago

    Edwards Lifesciences' Philanthropy Exceeds Every Heartbeat Matters Goal To Impact One Million Underserved People Ahead Of Schedule

    IRVINE, Calif., Sept. 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced at a 60th anniversary educational event that the Every Heartbeat Matters initiative has exceeded the goal to impact the global burden of heart valve disease by supporting the education, screening and treatment of one million underserved people by 2020. With the support of grants from Edwards Lifesciences Foundation and donations of Edwards heart valve technologies, the initiative is now expected to reach a total of 1.5 million underserved people globally by the 2020 target through the cumulative effort of 60 non-profit partners.

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: ABIOMED and Edwards Lifesciences

    The Trump administration imposed a tariff of 10 percent on over $200 billion, which could increase to 25 percent if the two countries are unable to settle, according to L. Thomas Block, Washington policy strategist at Fundstrat Global Advisors. The stock ended the day 7.67% higher at $165.47.

  • Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference
    PR Newswire2 months ago

    Edwards Lifesciences To Present At The 13th Annual Wells Fargo Healthcare Conference

    IRVINE, Calif. , Aug. 30, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
    PR Newswire3 months ago

    Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference

    IRVINE, Calif. , Aug. 2, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • ACCESSWIRE3 months ago

    Free Stock Performance Review on Boston Scientific and Three Additional Medical Equipment Stocks

    WallStEquities.com follows AxoGen Inc. (NASDAQ: AXGN), Boston Scientific Corp. (NYSE: BSX), Corindus Vascular Robotics Inc. (NYSE American: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments, such as dental and surgical appliances.

  • Edwards Lifesciences Reports Second Quarter Results
    PR Newswire3 months ago

    Edwards Lifesciences Reports Second Quarter Results

    IRVINE, Calif. , July 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...

  • Edwards Comments On CMS Advisory Panel
    PR Newswire3 months ago

    Edwards Comments On CMS Advisory Panel

    "Today's advisory panel meeting provided a review of current and possible future impacts of volume requirements on TAVR centers in the United States.  In the absence of definitive evidence linking high volumes of procedures to high quality outcomes for TAVR patients, we continue to believe the best course of action is to focus on defined quality measures for both new programs and also those continuing to offer this life-saving, less-invasive therapy.

  • Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018
    PR Newswire3 months ago

    Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018

    IRVINE, Calif. , July 12, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...

  • Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR
    PR Newswire4 months ago

    Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR

    CMS announced that it has opened the NCA to reconsider the National Coverage Determination (NCD) released in 2012 for TAVR. This development was clearly expected and the analysis will examine the extensive body of evidence regarding the clinical, economic and quality of life benefits of TAVR.

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Senseonics Holdings and Three More Medical Equipment Stocks

    Stock Research Monitor: EW, PBH, and VAR LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on SENS sign up now at www.wallstequities.com/registration . On Friday, June 22, 2018, ...

  • ACCESSWIRE5 months ago

    Complimentary Technical Snapshots on Avinger and Three More Medical Equipment Stocks

    Under evaluation this morning are these four stocks: Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), Corindus Vascular Robotics Inc. (NYSE AMER: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Redwood City, California headquartered Avinger Inc.'s stock finished last Friday's session 2.03% higher at $2.01.

  • Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference
    PR Newswire5 months ago

    Edwards Lifesciences To Present At The Bernstein 34th Annual Strategic Decisions Conference

    IRVINE, Calif. , May 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...

  • Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve
    PR Newswire5 months ago

    Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve

    Study comparison shows results of almost 2,000 intermediate-risk patients at more than 450 U.S. centers PARIS , May 22, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader ...

  • Edwards Announces Key Events For EuroPCR 2018
    PR Newswire5 months ago

    Edwards Announces Key Events For EuroPCR 2018

    PARIS , May 21, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced ...

  • Edwards Lifesciences To Webcast Annual Meeting Of Stockholders
    PR Newswire5 months ago

    Edwards Lifesciences To Webcast Annual Meeting Of Stockholders

    IRVINE, Calif. , May 14, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, will ...

  • ACCESSWIRE5 months ago

    Free Post Earnings Research Report: Edwards Lifesciences’ Adjusted Sales Grew 9.3%; Adjusted EPS Surged 30%

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free earnings report on Edwards Lifesciences Corp. (NYSE: EW), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EW. Edwards Lifesciences reported its first quarter fiscal 2018 operating and financial results on April 24, 2018. Additionally, the Company provided guidance for the upcoming quarter and fiscal year.

  • Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement
    PR Newswire6 months ago

    Edwards Lifesciences Enters Into Accelerated Share Repurchase Agreement

    Edwards Lifesciences, based in Irvine, Calif., is the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring.  Driven by a passion to help patients, the company collaborates with the world's leading clinicians and researchers to address unmet healthcare needs, working to improve patient outcomes and enhance lives. For more information, visit www.Edwards.com and follow us on Twitter @EdwardsLifesci.

  • Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy
    PR Newswire6 months ago

    Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy

    IRVINE, Calif., April 30, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction System for the treatment of tricuspid regurgitation. The Cardioband Tricuspid System is the first commercially available transcatheter therapy for the treatment of tricuspid heart valve disease. "Although open-heart surgical valve repair is practiced today, it has not been performed frequently for those suffering from tricuspid regurgitation, despite evidence of increased mortality in these patients," said Prof. Georg Nickenig, chief, Department of Cardiology, University Hospital, Bonn, Germany.

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswire6 months ago

    Edwards Lifesciences Reports First Quarter Results

    IRVINE, Calif. , April 24, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...

  • ACCESSWIRE6 months ago

    Edwards Lifesciences Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 24, 2018 / Edwards Lifesciences Corporation (NYSE: EW ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 24, 2018 at 5:00 PM Eastern ...

  • Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018
    PR Newswire6 months ago

    Edwards Lifesciences To Host Earnings Conference Call On April 24, 2018

    IRVINE, Calif. , April 10, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, ...